Geron discontinues Phase 3 IMpactMF myelofibrosis trial after independent committee advice
Geron Corporation said it will discontinue the Phase 3 IMpactMF trial of imetelstat in JAK inhibitor relapsed or refractory myelofibrosis, following a recommendation from the independent Data Monitoring Committee that the trial was unlikely to meet its primary overall survival endpoint. The company reported no new safety signals that change the known safety profile of imetelstat, and it will analyze the data before sharing findings at a future date.
Key points
- The independent Data Monitoring Committee advised that the trial was unlikely to meet its primary overall survival endpoint.
- The trial evaluated 327 patients with intermediate-2 or high-risk myelofibrosis who were relapsed or refractory to a JAK inhibitor.
- No new safety signals were observed that change the known safety profile of imetelstat.
- Geron says it will keep growing RYTELO demand in the U.S. and broaden access to eligible LR-MDS patients outside the U.S.
The filing
Written by AI on Nov 9, 2026, 8:28 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 28, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.